Fung DS, Whitson JT. An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy. Clinical Ophthalmology. 2014;8:543-54.
Rocha-Sousa A, Rodrigues-Araujo J, Gouveia P, et al. New therapeutic targets for intraocular pressure lowering. ISRN ophthalmology. 2013;2013:261386.
adcliffe NM. The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies. Clinical Ophthalmology. 2014;8:2541-9.
MK. Present and new treatment strategies in the management of flaucoma. The Open Ophthalmology Journal. 2015;9:89-100.
Doozandeh A, Yazdani S. Neuroprotection in glaucoma. J Ophthal Vision Res. 2016;11(2):209-20.
Knight OJ, Lawrence SD. Sustained drug delivery in glaucoma. Curr Opin Ophthalmol. 2014;25(2):112-7.
Wojcik-Gryciuk A, Skup M, Waleszczyk WJ. Glaucoma -state of the art and perspectives on treatment. Restorative Neurology and Neuroscience. 2015;34(1):107-23.
Inoue K. Managing adverse effects of glaucoma medications. Clinical Ophthalmology. 2014;8:903-913.
Bucolo C, Platania CB, Reibaldi M, et al. Controversies in glaucoma: current medical treatment and drug development. Current Pharmaceutical Design. 2015;21(32):4673-81.
Fang Y, Ling Z, Sun X. Fixed-combination treatments for intraocular hypertension in Chinese patients - focus on bimatoprost-timolol. Drug Design, Development and Therapy. 2015;9:2617-25.
Ting NS, Li Yim JF, Ng JY. Different strategies and cost-effectiveness in the treatment of primary open angle glaucoma. Clinico Economics and Outcomes Research. 2014;6:523-30.
Li T, Lindsley K, Rouse B, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis. Ophthalmology. 2016;123(1):129-40.
Sharma S, Trikha S, Perera SA, Aung T. Clinical effectiveness of brinzolamide 1%-brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension. Clinical Ophthalmology. 2015;9:2201-7.
Schehlein EM, Novack GD, Robin AL. New classes of glaucoma medications. Curr Opinion Ophthalmoly. November 2016. [Epub ahead of print].
Rhee DJ. Glaucoma: color atlas and synopsis of clinical ophthalmology. Wills Eye Hospital. 2003.
Peeters A, Schouten JS, Severens JL, et al. Latanoprost versus timolol as first choice therapy in patients with ocular hypertension. A cost-effectiveness analysis. Acta ophthalmologica. 2012;90(2):146- 54.
Daka Q, Trkulja V. Efficacy and tolerability of mono-compound topical treatments for reduction of intraocular pressure in patients with primary open angle glaucoma or ocular hypertension: an overview of reviews. Croatian Medical Journal. 2014;55(5):468-80.
Singh K, Lee BL, Wilson MR. A panel assessment of glaucoma management: modification of existing RAND-like methodology for consensus in ophthalmology. Part II: Results and interpretation. Am J Ophthalmol. 2008;145(3):575-81.
Barnebey HS, Robin AL. Adherence to fixed-combination versus unfixed Travoprost 0.004%/timolol 0.5% for glaucoma or ocular hypertension: a randomized trial. Am J Ophthalmol. December
[Epub ahead of print].
Tanna AP, Lin AB. Medical therapy for glaucoma: what to add after a prostaglandin analogs? Curr Opin Ophthalmol. 2015;26(2):116- 20.
Hollo G, Topouzis F, Fechtner RD. Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. Expert Opinion on Pharmacotherapy. 2014;15(12):1737-47.
Friedman DS, Quigley HA, Gelb L, et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthalmol Vis Sci. 2007;48(11):5052-7.
Fechtner RD, Khouri AS. Fixed combination: a mainstay of glaucoma management today and tomorrow. Glaucoma Today. 2016;14(6):33-6.
Newman-Casey PA, Robin AL, Blachley T, et al. The most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 2015;122(7):1308-16.
Araie M, Sforzolini BS, Vittitow J, Weinreb RN. Evaluation of the effect of latanoprostene bunod ophthalmic solution, 0.024% in lowering intraocular pressure over 24 h in healthy Japanese subjects. Advances in Therapy. 2015;32(11):1128-39.
Cavet ME, Vollmer TR, Harrington KL, et al. Regulation of endothelin- 1-induced trabecular meshwork cell contractility by latanoprostene bunod. Invest Ophthalmol Vis Sci. 2015;56(6):4108-16.
Glaucoma Research Foundation. New medical therapies for glaucoma.
www.glaucoma.org/treatment/new-medical-therapies- for-glaucoma.php. Accessed February 17, 2017.
Myers JS, Sall KN, DuBiner H, et al. A dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of 2 and 4 weeks of twice-daily ocular trabodenoson in adults with ocular hypertension or primary open-angle glaucoma. J Ocular Pharmacol Therapeutics. 2016;32(8):555-62.
Inotek announces top-line results for MATrX-1, first phase 3 trial of trabodenoson for glaucoma. Business Wire. January 3, 2017.
